Julie Hambleton

Dr. Julie Hambleton is a biotechnology and pharmaceutical executive with over 20 years of experience leading oncology companies. Most recently she served as interim chief executive officer at Arch Oncology. Previously, she served as senior vice president, chief medical officer and head of development at IDEAYA Biosciences. Prior to her role at IDEAYA, she held the positions of vice president and head of U.S. Medical at Bristol-Myers Squibb, executive vice president and chief medical officer at Five Prime Therapeutics and vice president of clinical development at Clovis Oncology. Dr. Hambleton began her industry career at Genentech, most recently as group medical director of global clinical development. She completed her medical and hematology-oncology training at the University California, San Francisco, where she then served on faculty from 1993 to 2003. She received a B.S. from Duke University, and M.D. from Case Western Reserve University School of Medicine and was Board-certified in Hematology and Internal Medicine.